Doctors Without Borders rejects ViiV Healthcare’s proposed contract for long-acting HIV PrEP drug

Med­ical ad­vo­ca­cy group Médecins Sans Fron­tières (MSF), al­so known as Doc­tors With­out Bor­ders, called up­on Vi­iV Health­care Thurs­day to cut a con­fi­den­tial­i­ty clause and re­vise sup­ply terms in a pro­posed pur­chase agree­ment for Vi­iV’s long-act­ing form of HIV drug cabote­gravir.

MSF said it placed a pur­chase or­der for the drug in Ju­ly 2022, af­ter FDA ap­proved the ex­tend­ed-re­lease ver­sion in Dec. 2021. MSF said that it be­gan good-faith ne­go­ti­a­tions with Vi­iV at that time to fi­nal­ize a re­quired pur­chase con­tract but af­ter months of ne­go­ti­a­tions, MSF said Vi­iV in­tro­duced “last-minute changes” to the agree­ment in May, which the or­ga­ni­za­tion said were not in line with oth­er agree­ments with man­u­fac­tur­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.